Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL

Campanella, A. ; Capasso, A. ; Heltai, S. ; Taccetti, C. ; Albi, E. ; Herishanu, Y. ; Haggenburg, S. ; Chatzikonstantinou, T. ; Doubek, M. ; Kättström, M. ; Giannopoulos, K. ; Simkovic, M. ; Moreno, C. ; Massaia, M. ; Bumbea, H. ; Alshemmari, S. ; Ranghetti, P. ; Perotta, E. ; Martini, F. ; Sant'Antonio, E. ; Colia, M. ; Combi, C. ; Levi, S. ; Kater, A. P. ; Hazenberg, M. ; Nijhof, I. S. ; Hofsink, Q. ; Demosthenous, C. ; Kotaskova, J. ; Zaleska, J. ; Vrbacky, F. ; Raya, A. Mora ; Bisogno, D. ; Tripoli, I. E. ; Popov, V. M. ; Roman, V. ; Stavroyianni, N. ; Karypidou, M. ; Scarano, E. ; Locatelli, M. ; Frenquelli, M. ; Scarfò, L. ; Stamatopoulos, K. ; Ghia, P.

American journal of hematology, 2024-04, Vol.99 (4), p.745-750 [Periódico revisado por pares]

Hoboken, USA: John Wiley & Sons, Inc

Texto completo disponível